---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Dosing and administration questions"
description: "Dosing and administration questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Premedication, Administration, Preparation, and IV vs subcutaneous. Questions: What is the Opdivo dose with Yervoy for first-line metastatic NSCLC? What is the Opdivo dose with Yervoy and chemotherapy for metastatic NSCLC? What is the Opdivo IV dose for previously treated metastatic NSCLC? What is the Opdivo Qvantig dose for metastatic NSCLC? 9 further questions follow. 13 questions quoted from 10 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Dosing and administration questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications](https://www.evicenter.com/medical-information/opdivo).

## Dosing

<a id="opdivo-dose-with-yervoy"></a>

### What is the Opdivo dose with Yervoy for first-line metastatic NSCLC?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “Metastatic non-small cell lung 
> cancer expressing PD-L1
> 360 mg every 3 weeks 
> with ipilimumab 1 mg/kg 
> every 6 weeks
> In combination with 
> ipilimumab until disease 
> progression, unacceptable 
> toxicity, or up to 2 years  
> in patients without disease 
> progression”

Source: [OPDIVO: OPDIVO, page 4, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=4)

> “<sup>§</sup>The recommended dosage of OPDIVO IV per the Prescribing Information is 360 mg q3w with YERVOY IV 1 mg/kg q6w.<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=recommended%20dosage%20of%20OPDIVO%20IV,with%20YERVOY%20IV%201%20mg%2Fkg)

<a id="opdivo-dose-with-yervoy-and-chemo"></a>

### What is the Opdivo dose with Yervoy and chemotherapy for metastatic NSCLC?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “Metastatic or recurrent  
> non-small cell lung cancer
> 360 mg every 3 weeks 
> with ipilimumab 1 mg/
> kg every 6 weeks and 
> histology-based platinum-
> doublet chemotherapy 
> every 3 weeks
> In combination with 
> ipilimumab until disease 
> progression, unacceptable 
> toxicity, or up to 2 years in 
> patients without disease 
> progression
> In combination with 
> histology-based platinum-
> doublet chemotherapy  
> for up to 2 cycles”

Source: [OPDIVO: OPDIVO, page 5, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=5)

> “On the first week, 4 agents will be administered (OPDIVO IV 360 mg + YERVOY IV 1 mg/kg + histology-based chemo<sup>‡</sup>), followed by 3 agents (OPDIVO IV + histology-based chemo<sup>‡</sup>) on the third week, 2 agents (OPDIVO IV + YERVOY IV) on the sixth week, and OPDIVO IV monotherapy on the ninth week, followed by maintenance therapy of OPDIVO IV + YERVOY IV<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Dosing for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/dosing#:~:text=On%20the%20first%20week%2C%204,of%20OPDIVO%20IV%20%2B%20YERVOY)

> “<sup>‡</sup>Histology-based chemo: SQ patients: carboplatin AUC 6 + paclitaxel 200 mg/m<sup>2</sup> q3w; NSQ patients: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m<sup>2</sup> or cisplatin 75 mg/m<sup>2</sup> + pemetrexed 500 mg/m<sup>2</sup> q3w.<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Dosing for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/dosing#:~:text=chemo%3A%20SQ%20patients%3A%20carboplatin%20AUC,pemetrexed%20500)

<a id="opdivo-dose-second-line"></a>

### What is the Opdivo IV dose for previously treated metastatic NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “Metastatic non-small cell lung cancer
> 240 mg every 2 weeks
> or 
> 480 mg every 4 weeks
> Until disease 
> progression or 
> unacceptable 
> toxicity”

Source: [OPDIVO: OPDIVO, page 4, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=4)

> “<sup>‡</sup>The recommended dose of OPDIVO is either 240 mg every 2 weeks or 480 mg every 4 weeks administered as an IV infusion over 30 minutes until disease progression or unacceptable toxicity.<sup>1</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy?tabKey=oivcheckmate057and017#:~:text=recommended%20dose%20of%20OPDIVO%20is,until%20disease%20progression%20or%20unacceptable)

<a id="opdivo-qvantig-dose"></a>

### What is the Opdivo Qvantig dose for metastatic NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “• Metastatic non-small cell lung cancer
> 	• 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.3)”

Source: [OPDIVO: OPDIVO Qvantig, page 1, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=1)

> “OPDIVO Qvantig is administered as a 3- to 5-minute subcutaneous injection<sup>1</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=OPDIVO%20Qvantig%20is%20administered%20as%20a%203%2D%20to%205%2Dminute%20subcutaneous)

<a id="opdivo-dose-modifications"></a>

### Is the Opdivo dose reduced for side effects?

> “No dose reduction for OPDIVO IV or YERVOY IV is recommended.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=No%20dose%20reduction%20for%20OPDIVO%20IV%20or%20YERVOY%20IV%20is%20recommended.)

> “In general, withhold OPDIVO IV and YERVOY IV for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue OPDIVO IV and YERVOY IV for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, persistent moderate (Grade 2) or severe (Grade 3) reactions lasting 12 weeks or longer after last YERVOY IV dose (excluding endocrinopathy), or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=In%20general%2C%20withhold%20OPDIVO%20IV,12%20weeks%20of%20initiating%20steroids.)

> “No dose reduction for OPDIVO IV is recommended.”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing?tabKey=opdivoiv#:~:text=No%20dose%20reduction%20for%20OPDIVO%20IV%20is%20recommended.)

> “No dose reduction for OPDIVO Qvantig is recommended.”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=No%20dose%20reduction%20for%20OPDIVO%20Qvantig%20is%20recommended.)

## Premedication

<a id="opdivo-premedication"></a>

### Do Opdivo or Opdivo Qvantig require premedication?

> “No premedication required with OPDIVO IV + YERVOY IV”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=No%20premedication%20required%20with%20OPDIVO%20IV%20%2B%20YERVOY%20IV)

> “No premedication required”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing?tabKey=opdivoiv#:~:text=No%20premedication%20required)

> “No premedication required<sup>1</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=No%20premedication)

Note: The second passage is from the Opdivo IV monotherapy dosing section and the third from the Opdivo Qvantig dosing section.

## Administration

<a id="opdivo-infusion-time"></a>

### How long does an Opdivo infusion take?

> “*OPDIVO is administered as an IV infusion over 30 minutes.<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=%2AOPDIVO%20is%20administered%20as%20an%20IV%20infusion%20over%2030)

> “Administer the infusion over 30 minutes through an IV line containing a sterile, non-pyrogenic, low protein binding, in-line filter (pore size of 0.2–1.2 micrometers)”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=Administer%20the%20infusion%20over%2030,%28pore%20size%20of%200.2%E2%80%931.2%20micrometers%29)

<a id="opdivo-administration-order"></a>

### In what order are Opdivo, Yervoy, and chemotherapy given?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “With YERVOY IV: administer OPDIVO IV first followed by YERVOY IV on the same day”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=With%20YERVOY%20IV%3A%20administer%20OPDIVO,IV%20on%20the%20same%20day)

> “With YERVOY IV and platinum-doublet chemotherapy: administer OPDIVO IV first followed by YERVOY IV and then platinum-doublet chemotherapy on the same day”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=With%20YERVOY%20IV%20and%20platinum%2Ddoublet,chemotherapy%20on%20the%20same%20day)

> “Use separate infusion bags and filters for each infusion
> Do not coadminister other drugs through the same IV line
> Flush the entire IV line at the end of infusion”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=Use%20separate%20infusion%20bags%20and,at%20the%20end%20of%20infusion)

<a id="opdivo-qvantig-administration"></a>

### How is Opdivo Qvantig injected?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “Administer the full contents of the syringe into the subcutaneous tissue of 1 of the 4 quadrants of the abdomen, or thigh over a period of 3 to 5 minutes
> Alternate injection sites across the 4 quadrants of the abdomen or thighs for successive injections. Do not inject into areas where the skin is tender, red, or bruised, or areas where there are scars or moles. If the administration of OPDIVO Qvantig is interrupted, continue administering at the same site, or at an alternate site
> During treatment with OPDIVO Qvantig, do not administer other subcutaneous medications at the same site used for OPDIVO Qvantig”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=Administer%20the%20full%20contents%20of,site%20used%20for%20OPDIVO%20Qvantig)

<a id="opdivo-qvantig-not-intravenous"></a>

### Can Opdivo Qvantig be given intravenously?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is OPDIVO Qvantig for subcutaneous use and NOT intravenous nivolumab. Do NOT administer  OPDIVO Qvantig intravenously. OPDIVO Qvantig should be administered by a healthcare professional.”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=To%20prevent%20medication%20errors%2C%20check,administered%20by%20a%20healthcare%20professional.)

> “• OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) has different dosage and 
> administration instructions than intravenous nivolumab products. 
> 	• OPDIVO QVANTIG is for subcutaneous use only in the abdomen or thigh. 
> 	• OPDIVO QVANTIG is to be administered by a healthcare professional only. (2.1)”

Source: [OPDIVO: OPDIVO Qvantig, page 1, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=1)

## Preparation

<a id="opdivo-preparation"></a>

### How is Opdivo IV prepared for infusion?

> “Visually inspect drug product solution for particulate matter and discoloration prior to administration. OPDIVO IV is a clear to opalescent, colorless to pale-yellow solution. Discard the vial if the solution is cloudy, is discolored, or contains extraneous particulate matter other than a few translucent-to-white, proteinaceous particles. Do not shake the vial.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=Visually%20inspect%20drug%20product%20solution,Do%20not%20shake%20the%20vial.)

> “Withdraw the required volume of OPDIVO IV and transfer into an intravenous container
> Dilute OPDIVO IV with either 0.9% sodium chloride injection, USP or 5% dextrose injection, USP to prepare an infusion with a final concentration ranging from 1 mg/mL to 10 mg/mL. The total volume of infusion must not exceed 160 mL
> For adult and pediatric patients with body weight ≥40 kg, do not exceed a total volume of infusion of 160 mL
> For adult and pediatric patients with body weight <40 kg, the total volume of infusion must not exceed 4 mL/kg of body weight
> Mix diluted solution by gentle inversion. Do not shake
> Discard partially used vials or empty vials of OPDIVO IV”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Dosing for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/dosing#:~:text=Withdraw%20the%20required%20volume%20of,empty%20vials%20of%20OPDIVO%20IV)

<a id="opdivo-qvantig-preparation"></a>

### How is Opdivo Qvantig prepared?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “Each OPDIVO Qvantig vial is for one-time use only. It is a ready-to-use solution for injection. It should not be diluted.
>
> Visually inspect for particulate matter and discoloration prior to administration. OPDIVO Qvantig is a clear to opalescent, colorless to yellow solution. Discard if the solution is discolored or contains extraneous particulate matter other than a few translucent-to-white particles. Do not shake.”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=Each%20OPDIVO%20Qvantig%20vial%20is,translucent%2Dto%2Dwhite%20particles.%20Do%20not%20shake.)

> “Calculate the appropriate number of vials of OPDIVO Qvantig (300 mg/5,000 units and/or 600 mg/10,000 units) needed based on the prescribed dose.
>
> Allow vial(s) to reach room temperature 20°C to 25°C (68°F to 77°F) before withdrawing dose.
>
>
> 300 mg nivolumab and 5,000 units hyaluronidase
> Withdraw 2.5 mL from the 300 mg/5,000 units vial of OPDIVO Qvantig into the syringe
> 600 mg nivolumab and 10,000 units hyaluronidase
> Withdraw 5 mL from the 600 mg/10,000 units vial of OPDIVO Qvantig into the syringe
> 900 mg nivolumab and 15,000 units hyaluronidase
> Withdraw 5 mL from the 600 mg/10,000 units vial and 2.5 mL from the 300 mg/5,000 units vial of OPDIVO Qvantig into a single syringe for a total volume of 7.5 mL
> 1,200 mg nivolumab and 20,000 units hyaluronidase
> Withdraw 5 mL from each vial of 600 mg/10,000 units OPDIVO Qvantig into a single syringe for a total volume of 10 mL
>
> Select the appropriate syringe label provided in the carton that matches the prescribed dose and apply to the prepared syringe.
>
> Discard partially used or empty vials of OPDIVO Qvantig.”

Source: [OPDIVO: OPDIVO Qvantig® Dosing & Administration for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/dosing#:~:text=Calculate%20the%20appropriate%20number%20of,empty%20vials%20of%20OPDIVO%20Qvantig.)

## IV vs subcutaneous

<a id="opdivo-qvantig-vs-iv-time"></a>

### How long does Opdivo Qvantig take to give compared with Opdivo IV?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “<sup>†</sup>A 3- to 5-minute injection of OPDIVO Qvantig compared with a 30-minute infusion of IV OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary.<sup>1,2</sup>”

Source: [OPDIVO: OPDIVO Qvantig® & OPDIVO® (nivolumab) | For HCPs, captured 2026-11-13](https://www.opdivohcp.com/#:~:text=3%2D%20to%205%2Dminute%20injection%20of,time.%20Actual%20clinic%20time%20may)

> “<sup>§</sup>No IV preparation, dilution, weight-based dose calculations or port access required with OPDIVO Qvantig.<sup>2</sup>”

Source: [OPDIVO: Subcutaneous Injection, captured 2026-11-13](https://www.opdivohcp.com/qvantig#:~:text=IV%20preparation%2C%20dilution%2C%20weight%2Dbased%20dose%20calculations%20or%20port%20access%20required%20with%20OPDIVO)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
